VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating participants with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Condition or disease	Intervention/treatment	Phase
Squamous Cell Carcinoma of the Head and Neck	Biological: VX15/2503; Biological: Ipilimumab; Biological: Nivolumab	Phase 1

Detailed Description:

PRIMARY OBJECTIVE:

To evaluate the effect of VX15/2503 alone and VX15/2503 in combination with immune checkpoint inhibitors, ipilimumab or nivolumab, on the immune profile in the tumor microenvironment and in peripheral blood.

SECONDARY OBJECTIVE:

To extend the previously reported safety profile of single agent VX15/2503 to the combination of VX15/2503 and immune checkpoint inhibitors, ipilimumab or nivolumab, in patients with head and neck squamous cell carcinoma.

OUTLINE: Participants are randomized to 1 of 6 groups.

GROUP A: Participants receive VX15/2503 intravenously (IV) over 60 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.

GROUP B: Participants receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.

GROUP C: Participants receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.

GROUP D: Participants receive nivolumab IV over 60 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.

GROUP E: Participants receive ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.

GROUP F: Participants undergo standard of care surgery.

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	36 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Actual Study Start Date :	November 1, 2018
Estimated Primary Completion Date :	November 30, 2020
Estimated Study Completion Date :	November 30, 2020

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Group A (VX15/2503); Participants receive VX15/2503 IV over 60 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.	Biological: VX15/2503; Given IV; Other Names: moAb VX15/2503; Anti-SEMA4D Monoclonal Antibody VX15/2503
Experimental: Group B (VX15/2503, ipilimumab); Participants receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.	Biological: VX15/2503; Given IV; Other Names: moAb VX15/2503; Anti-SEMA4D Monoclonal Antibody VX15/2503; Biological: Ipilimumab; Given IV; Other Names: BMS-734016; MDX-010; MDX-CTLA4; Yervoy
Experimental: Group C (VX15/2503, nivolumab); Participants receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.	Biological: VX15/2503; Given IV; Other Names: moAb VX15/2503; Anti-SEMA4D Monoclonal Antibody VX15/2503; Biological: Nivolumab; Given IV; Other Names: BMS-936558; MDX-1106; NIVO; ONO-4538; Opdivo
Experimental: Group D (nivolumab); Participants receive nivolumab IV over 60 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.	Biological: Nivolumab; Given IV; Other Names: BMS-936558; MDX-1106; NIVO; ONO-4538; Opdivo
Experimental: Group E (ipilimumab); Participants receive ipilimumab IV over 90 minutes on day 1. Beginning days 22-36, participants undergo standard of care surgery.	Biological: Ipilimumab; Given IV; Other Names: BMS-734016; MDX-010; MDX-CTLA4; Yervoy
No Intervention: Group F (no treatment); Participants undergo standard of care surgery.

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Change in immune profile in the tumor microenvironment [ Time Frame: Baseline up to 4-8 weeks after surgery ]
   Specimens from surgical resection will be collected under the guidance of the collaborating pathologist and tissue procurement staff at the time of surgery to capture tissue in excess of that needed for clinical staging and diagnostic purposes. Tumor specimens will be fixed in 10% formalin, embedded in paraffin and biomarkers related to activated HNSCC stroma will be assessed via immunohistochemical analysis.
2. Change in circulating percentage of immune suppressor subsets in peripheral blood [ Time Frame: Baseline up to 4-8 weeks after surgery ]
   Blood samples will be collected and peripheral blood mononuclear cells will be isolated from these samples and stored in -80°C freezers until analysis. Multi-parameter flow cytometry will be utilized to phenotype immune effector cells. The impact of treatment on the circulating percentage of immune suppressor subsets that may serve as predictors of response to immune checkpoint inhibition. All data will be expressed as the percentage of total circulating peripheral blood cells with each respective phenotype.
3. Phenotypic shifts in T lymphocyte subsets in peripheral blood [ Time Frame: Baseline up to 4-8 weeks after surgery ]
   Blood samples will be collected and peripheral blood mononuclear cells will be isolated from these samples and stored in -80°C freezers until analysis. Blood will be analyzed by multi-parameter flow cytometry to identify systemic phenotypic shifts mediated by VX15/2503 in combination with immune checkpoint inhibition.

Secondary Outcome Measures :

1. Incidence of adverse events assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 4-8 weeks after surgery ]
   Adverse events will be classified using MedDRA System Organ Classes and Preferred Terms. Furthermore, serious adverse events, adverse events (AEs) with a severity grade of 3 or above using NCI CTCAE version 4.0, AEs deemed related to study drug, AEs leading to discontinuation of study drug, and AEs leading to death will also be summarized in preferred term by system organ class and listed on an individual subject basis.

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Stage I-IVA cytologically or histologically-proven head and neck squamous cell carcinoma (HNSCC), p16 positive and negative allowed
• Oropharyngeal tumors must have p16 testing done
• Cancer confirmed to be surgically resectable, with surgery evaluation with planned resection
• Archival tissue prior to treatment available from at most 6 months prior to study enrollment. Otherwise new pre-treatment biopsy mandatory
• No prior lines of therapy
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Absolute neutrophil count ≥ 1,500 cells/µL
• Platelets ≥ 100,000/µL
• Hemoglobin ≥ 9.0g/dL (may receive packed red blood cell [prbc] transfusion)
• Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
• Albumin ≥ 3.0 g/dL
• Serum creatinine ≤ 1.5 x ULN
• Calculated creatinine clearance of ≤ 50 mL/min
• International normalized ratio (INR) ≤ 1.5. Anticoagulation is allowed only with low molecular weight heparin (LMWH). Patient receiving LMW heparin on stable therapeutic dose for more than 2 weeks or with factor Xa level < 1.1 units/mL (U/mL) are allowed on the trial
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
• Ability to understand and willingness to sign a written informed consent document
• Female subjects of childbearing potential must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and 3 months after completion
• Male subjects must agree to use adequate contraception (e.g., condoms; abstinence) for the duration of study treatment and 3 months after completion
• Female subjects of childbearing age must have a negative serum pregnancy test at study entry

Exclusion Criteria:

• Poor venous access for study drug administration
• Nasopharynx cancer, cancer of unknown primary, sinonasal cancer
• Determined not to be a surgical candidate due to medical co-morbidities
• Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)
• Prior organ allograft or allogeneic bone marrow transplantation
• Subjects with any active autoimmune disease or history of known or suspected autoimmune disease except for subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
• Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
• Women who are pregnant or lactating
• Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study
• Clinical evidence of bleeding diathesis or coagulopathy
• Patients with prior malignancies, including pelvic cancer, are eligible if they have been disease free for > 5 years. Patients with prior in situ carcinomas are eligible provided there was complete removal
• Active bacterial or fungal infections requiring systemic treatment within 7 days of treatment
• Use of other investigational drugs (drugs not marked for any indication) within 28 days or at least 5 half-lives (whichever is longer) before study drug administration
• History of severe hypersensitivity reactions to other monoclonal antibodies
• Non-oncology vaccines within 28 days prior to or after any dose of ipilimumab
• No archival tissue available pre-study treatment, and repeat biopsy not feasible

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Conor Steuer, MD	404-778-4995	csteuer@emory.edu

Locations

United States, Georgia
Emory University Hospital Midtown	Recruiting
Atlanta, Georgia, United States, 30308
Contact: Rebecca Holman 404-686-2553 rebecca.b.holman@emory.edu
Contact: Swathi Chinaranagari 404-686-0239 swathi.chinaranagari@emory.edu
Emory University Hospital/Winship Cancer Institute	Recruiting
Atlanta, Georgia, United States, 30322
Contact: Shantina Walls 404-778-4995 shantina.n.walls@emory.edu

Sponsors and Collaborators

Emory University

Vaccinex Inc.

Investigators

Principal Investigator:	Conor Steuer, MD	Emory University

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Conor Steuer, Principal Investigator, Emory University
ClinicalTrials.gov Identifier:	NCT03690986 History of Changes
Other Study ID Numbers:	IRB00103534; NCI-2018-01263 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); Winship4402-18 ( Other Identifier: Emory University Hospital/Winship Cancer Institute )
First Posted:	October 1, 2018
Last Update Posted:	November 14, 2018
Last Verified:	November 2018

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Additional relevant MeSH terms:

Carcinoma, Squamous Cell; Head and Neck Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell	Neoplasms by Site; Nivolumab; Antibodies, Monoclonal; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs